Echo starts clinical trial of one-piece biosensor for diabetes
This article was originally published in Clinica
Executive Summary
Echo Therapeutics has begun a clinical trial of a one-piece version of its noninvasive wireless Symphony transdermal continuous glucose monitoring (tCGM) system in patients with type 1 and 2 diabetes. Earlier studies used a prototype two-piece biosensor, and Echo (Franklin, Massachusetts) hopes that the new device will show "improved performance and reliability". The trial, which is expected to report results this quarter, will also evaluate the company's Prelude skin preparation system for transdermal drug delivery. It will collect approximately 900 data pairs from diabetes patients, and compare results from the Symphony system with the gold-standard YSI Glucose Analyzer.